These forums are designated to serve as a venue for discussion among patients, advocates, and clinicians. NATF's goal in hosting these forums is to increase dialogue on and awareness of thrombosis-related diseases, and to provide a bridge between patients who have questions and the clinicians who can answer them.

All NATF members are invited to participate in the forum, and membership is free! If you are not yet a member and would like to join forum discussions, please click on Register

After registering you will be able to access each forum and view current and previous topics of discussion.

e-Thrombosis for Healthcare Professionals

"Representative Waxman of the U.S. House of Representatives has recently introduced a "Promoting Innovation and Access to Life-Saving Medicine Act," which would allow the FDA to "approve abbreviated applications" for "biosimilar" and "biogeneric" products. While the rushed approval of such products sounds promising for increasing availability and decreasing costs of biologics, what about in the case of heparin, an animal-derived product? Is this a smart step towards reducing healthcare costs or an irresponsible and potentially dangerous idea?"

Post a new topic
  • Topics
    Replies
    Views
    Last post
Post a new topic

Return to Board index

Who is online

Users browsing this forum: No registered users and 1 guest

Forum permissions

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

© 2008 North American Thrombosis Forum
Terms of Use
Powered by phpBB
cron